developing patient-specific mrd markers for predicting and preventing mds relapse post-sct
Published 2 months ago • 51 plays • Length 3:16Download video MP4
Download video MP3
Similar videos
-
3:22
the impact of mrd as a biomarker
-
3:35
minimal residual disease (mrd) as a prognostic factor for acute myeloid leukemia (aml)
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
2:22
improve study: mrd assessment as an endpoint to define treatment length and intensity in cll
-
1:52
improving the use of mrd for the prognosis and treatment of all
-
2:57
imetelstat for lr-mds: insights from the imerge trial
-
2:40
imerge results: efficacy and disease-modifying activity of imetelstat in lr-mds after esa failure
-
3:07
minimal residual disease (mrd)
-
1:16
state of the art: mds
-
3:35
the potential of mrd as a surrogate marker in randomized trials to accelerate drug approvals
-
1:57
combining molecular and clinical data to predict survival & transformation risk in patients with mds
-
2:18
the utility of measurable residual disease (mrd) assessment in acute myeloid leukemia (aml)
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:17
mrd measurement as a strategy for treatment-free survival
-
1:41
an overview of the mds diagnosis pathway
-
2:35
mrd focus: why measurable residual disease testing is the future
-
4:35
learn about measurable residual disease (mrd)
-
2:03
updated fda mrd guidelines for hematological malignancies
-
2:23
the use of immunophenotyping to assess minimal residual disease (mrd) in multiple myeloma
-
1:46
standardization mrd monitoring in clinical trials
-
4:42
predicting mrd outcomes in myeloma using machine learning